BioXcel Therapeutics (BTAI) Operating Income (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Operating Income of -$10.2 million for Q1 2026, down 1.23% year-over-year from -$10.4 million in Q1 2025, and up 0.57% quarter-over-quarter from -$10.3 million in Q4 2025.
BioXcel Therapeutics (BTAI) Operating Income (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Operating Income history runs 10 years deep, the most recent figure standing at -$10.2 million for Q1 2026.
- In Q1 2026, Operating Income fell 1.23% year-over-year to -$10.2 million; the TTM figure through Mar 2026 stood at -$50.6 million (up 4.88% YoY), while the FY2025 annual figure was -$50.5 million, up 24.96% from the prior year.
- Operating Income for Q1 2026 stood at -$10.2 million, up from -$10.3 million in the prior quarter.
- The five-year high for Operating Income was -$10.1 million in Q1 2025, with the low at -$52.9 million in Q4 2022.
- The 5-year median for Operating Income is -$19.9 million (2023), against an average of -$27.0 million.
- The sharpest annual moves came in 2022 and 2024: Operating Income tumbled 102.42% in 2022, then jumped 68.34% in 2024.
- BioXcel Therapeutics' Operating Income stood at -$52.9 million in 2022, then soared by 62.42% to -$19.9 million in 2023, then surged by 47.21% to -$10.5 million in 2024, then advanced by 2.01% to -$10.3 million in 2025, then climbed by 0.57% to -$10.2 million in 2026.
- Business Quant data shows BTAI's Operating Income at -$10.2 million in Q1 2026, -$10.3 million in Q4 2025, and -$14.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.30 Mn | 24.30 Mn | 160,000.00 | -10.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.19 Mn |
| Mar 31, 2026 | -10.22 Mn |
| Dec 31, 2025 | -10.28 Mn |
| Sep 30, 2025 | -14.23 Mn |
| Jun 30, 2025 | -15.85 Mn |
| Mar 31, 2025 | -10.10 Mn |
| Dec 31, 2024 | -10.49 Mn |
| Sep 30, 2024 | -15.29 Mn |
| Jun 30, 2024 | -17.30 Mn |
| Mar 31, 2024 | -24.16 Mn |
| Dec 31, 2023 | -19.88 Mn |
| Sep 30, 2023 | -48.30 Mn |
| Jun 30, 2023 | -52.41 Mn |
| Mar 31, 2023 | -51.20 Mn |
| Dec 31, 2022 | -52.89 Mn |
| Sep 30, 2022 | -38.99 Mn |
| Jun 30, 2022 | -36.29 Mn |
| Mar 31, 2022 | -31.48 Mn |
| Dec 31, 2021 | -26.13 Mn |
| Sep 30, 2021 | -26.81 Mn |